Theolytics

We are proud to share that we have been awarded funding from Innovate UK’s Transforming Cancer Therapeutics Grants Call to support the advancement of next-generation immunotherapies for cancer. Looking forward to another great collaboration with Innovate UK! #oncolyticvirus #cancerimmunotherapy #ovariancancer #ukbiotech https://lnkd.in/ePgUm49k

Today we say a fond farewell and thank you to Charlotte Casebourne Stock, Co-Founder and CEO, as she moves on to her next entrepreneurial endeavor. At Theolytics; she has built a fantastic team founded on great science with an exciting program poised to move into the clinic this year.  Charlotte will transition into an advisory role with the company, stepping down as CEO. Mike Grey, Executive Chair, will assume overall leadership responsibility until further notice. Full details: https://lnkd.in/eSis-t2g

📣We are seeking a Senior Scientist Bioassay Validation to join our team📣 🌟At Theolytics we are developing next-generation cancer therapies. Our lead program is a next-generation oncolytic adenovirus being developed for ovarian cancer. 🥼We are looking for a Bioassay Validation Specialist Senior Scientist, with a good understanding of GCLP requirements, to join our team. 🎯This position represents an excellent opportunity for someone looking to take responsibility in a fast-paced environment, working within an interdisciplinary team to develop new cancer treatments. ❔Think this could be for you? We’d love to hear from you! 📝Apply now and join us on our exciting journey! #Bioassayvalidation #Biomarker #Hiring #OxfordBiotech #GCLP https://lnkd.in/gFpmWTZ3

📣We are seeking a Senior Scientist Bioassay Validation to join our team📣 🌟At Theolytics we are developing next-generation cancer therapies. Our lead program is a next-generation oncolytic adenovirus being developed for ovarian cancer. 🥼We are looking for a Bioassay Validation Specialist Senior Scientist, with a good understanding of GCLP requirements, to join our team. 🎯This position represents an excellent opportunity for someone looking to take responsibility in a fast-paced environment, working within an interdisciplinary team to develop new cancer treatments. ❔Think this could be for you? We’d love to hear from you! 📝Apply now and join us on our exciting journey! #Bioassayvalidation #Biomarker #Hiring #OxfordBiotech #GCLP https://lnkd.in/gFpmWTZ3

Today, May 8th, is World Ovarian Cancer Day. There is a clear need for new therapies to support everyone impacted by ovarian cancer and at Theolytics we strongly support the theme of “No Woman Left Behind”. We are working hard towards our goal to develop innovative new treatment options for women with ovarian cancer, including our lead candidate THEO-260 which is set to enter the clinic this year. Together, we hope to create an impact and contribute to a future where no woman has to fear this disease.   #NoWomanLeftBehind #WOCD2024 #WorldOvarianCancerDay #CancerImmunotherapy #OvarianCancer #Oncolyticvirus

We’re on the brink of a step-change for the oncolytic virus field. In biotech, the resilience and the creativity required to navigate through the concept-to-clinic journey is a function of the people - it takes a great team, and I'm delighted to welcome Sound Bioventures to Theolytics as a new investor. #biotech #oncology #viraltherapy

📣We're seeking a Senior Clinical Trials Manager to join our team📣   🌟At Theolytics we are developing next-generation cancer therapies. Our lead program is a next-generation oncolytic adenovirus being developed for ovarian cancer. 🎯We are looking for someone with clinical trial operational experience who is a self-starter, can drive results through coordinating effectively with a diverse, international set of stakeholders, and is happy to jump in when required in what will be an exciting work environment. 🥼This person will be a key contributor to clinical operations activities within Theolytics ❔Think this could be for you? We’d love to hear from you! 📝Apply now and join us on our exciting journey! https://lnkd.in/gyMGjfgU

📣We're seeking a Senior Clinical Trials Manager to join our team📣   🌟At Theolytics we are developing next-generation cancer therapies. Our lead program is a next-generation oncolytic adenovirus being developed for ovarian cancer. 🎯We are looking for someone with clinical trial operational experience who is a self-starter, can drive results through coordinating effectively with a diverse, international set of stakeholders, and is happy to jump in when required in what will be an exciting work environment. 🥼This person will be a key contributor to clinical operations activities within Theolytics ❔Think this could be for you? We’d love to hear from you! 📝Apply now and join us on our exciting journey! https://lnkd.in/gyMGjfgU

🎉 Exciting News! 🚀 We're thrilled to announce that Theolytics has successfully closed our latest financing round and delighted to welcome Sound Bioventures as a new investor! We are incredibly grateful for the support and trust of our investors, M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and The University of Oxford, and the continued contributions from our partners, and team members who have been instrumental in reaching this milestone. This funding enables us to advance our lead candidate THEO-260 through to clinical proof of concept. We're excited to advance a promising new cancer therapy for Ovarian Cancer into the clinic in 2024 and look forward to creating impact together! #Financing #Milestone #Cancerimmunotherapy #OvarianCancer #Biotech #Biotechnews #Oncolyticvirus https://lnkd.in/eBK-bNue

We are delighted to announce that Mike Grey has joined Theolytics' Board. Mike brings a track record across all stages of drug development which will be invaluable as we progress our lead programme into the clinic this year. More information about Mike Grey and Theolytics here: https://lnkd.in/eCiu-B79 #Biotechnews #Theolytics #Oncolyticvirus #Ovariancancer #UKbiotech